Do analysts recommend MGNX or CALT?

MacroGenics presently has a consensus target price of $5.50, indicating a potential upside of 15.06%. Given MacroGenics' stronger consensus rating and higher probable upside, equities research analysts plainly believe MacroGenics is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MacroGenics 1 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.29 Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is SVRA or MGNX more profitable?

Savara has a net margin of 0.00% compared to MacroGenics' net margin of -44.79%. Savara's return on equity of -87.19% beat MacroGenics' return on equity. Company Net Margins Return on Equity Return on Assets Savara N/A -87.19% -66.42% MacroGenics -44.79% -147.80% -28.40%

Does the media favor WVE or MGNX?

In the previous week, WAVE Life Sciences and WAVE Life Sciences both had 2 articles in the media. WAVE Life Sciences' average media sentiment score of 0.50 beat MacroGenics' score of 0.00 indicating that WAVE Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment WAVE Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MacroGenics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

MacroGenics (MGNX) Competitors

$4.78 +0.09 (+1.92%)

Closing price 04:00 PM Eastern

Extended Trading

$4.93 +0.15 (+3.14%)

As of 07:54 PM Eastern

Compare

MGNX vs. CALT, SVRA, PURR, WVE, and COLL

Should you buy MacroGenics stock or one of its competitors? MarketBeat compares MacroGenics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MacroGenics include Calliditas Therapeutics AB (publ) (CALT), Savara (SVRA), Hyperliquid Strategies (PURR), WAVE Life Sciences (WVE), and Collegium Pharmaceutical (COLL). These companies are all part of the "pharmaceutical products" industry.

How does MacroGenics compare to Calliditas Therapeutics AB (publ)?

MacroGenics (NASDAQ:MGNX) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

MacroGenics presently has a consensus target price of $5.50, indicating a potential upside of 15.06%. Given MacroGenics' stronger consensus rating and higher probable upside, equities research analysts plainly believe MacroGenics is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

MacroGenics has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market.

In the previous week, MacroGenics had 2 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 2 mentions for MacroGenics and 0 mentions for Calliditas Therapeutics AB (publ). MacroGenics' average media sentiment score of 0.00 equaled Calliditas Therapeutics AB (publ)'saverage media sentiment score.

Company	Overall Sentiment
MacroGenics	Neutral
Calliditas Therapeutics AB (publ)	Neutral

Calliditas Therapeutics AB (publ) has a net margin of -30.18% compared to MacroGenics' net margin of -44.79%. MacroGenics' return on equity of -147.80% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MacroGenics	-44.79%	-147.80%	-28.40%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

Calliditas Therapeutics AB (publ) has higher revenue and earnings than MacroGenics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$149.50M	2.03	-$74.62M	-$1.10	N/A
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

96.9% of MacroGenics shares are held by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 13.6% of MacroGenics shares are held by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

MacroGenics beats Calliditas Therapeutics AB (publ) on 10 of the 15 factors compared between the two stocks.

How does MacroGenics compare to Savara?

Savara (NASDAQ:SVRA) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

87.9% of Savara shares are held by institutional investors. Comparatively, 96.9% of MacroGenics shares are held by institutional investors. 5.3% of Savara shares are held by insiders. Comparatively, 13.6% of MacroGenics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

MacroGenics has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.56	N/A
MacroGenics	$149.50M	2.03	-$74.62M	-$1.10	N/A

In the previous week, MacroGenics had 2 more articles in the media than Savara. MarketBeat recorded 2 mentions for MacroGenics and 0 mentions for Savara. Savara's average media sentiment score of 0.00 equaled MacroGenics'average media sentiment score.

Company	Overall Sentiment
Savara	Neutral
MacroGenics	Neutral

Savara has a beta of 0.26, suggesting that its stock price is 74% less volatile than the broader market. Comparatively, MacroGenics has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market.

Savara has a net margin of 0.00% compared to MacroGenics' net margin of -44.79%. Savara's return on equity of -87.19% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-87.19%	-66.42%
MacroGenics	-44.79%	-147.80%	-28.40%

Savara presently has a consensus target price of $10.14, indicating a potential upside of 73.98%. MacroGenics has a consensus target price of $5.50, indicating a potential upside of 15.06%. Given Savara's stronger consensus rating and higher possible upside, research analysts clearly believe Savara is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Summary

Savara and MacroGenics tied by winning 7 of the 14 factors compared between the two stocks.

How does MacroGenics compare to Hyperliquid Strategies?

Hyperliquid Strategies (NASDAQ:PURR) and MacroGenics (NASDAQ:MGNX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

Hyperliquid Strategies has higher earnings, but lower revenue than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperliquid Strategies	$1M	1,141.16	-$16.01M	-$7.37	N/A
MacroGenics	$149.50M	2.03	-$74.62M	-$1.10	N/A

In the previous week, MacroGenics had 1 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 2 mentions for MacroGenics and 1 mentions for Hyperliquid Strategies. Hyperliquid Strategies' average media sentiment score of 0.64 beat MacroGenics' score of 0.00 indicating that Hyperliquid Strategies is being referred to more favorably in the media.

Company	Overall Sentiment
Hyperliquid Strategies	Positive
MacroGenics	Neutral

Hyperliquid Strategies currently has a consensus price target of $9.25, suggesting a potential upside of 17.09%. MacroGenics has a consensus price target of $5.50, suggesting a potential upside of 15.06%. Given Hyperliquid Strategies' stronger consensus rating and higher possible upside, equities analysts clearly believe Hyperliquid Strategies is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Hyperliquid Strategies has a net margin of 0.00% compared to MacroGenics' net margin of -44.79%. Hyperliquid Strategies' return on equity of -56.04% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperliquid Strategies	N/A	-56.04%	-52.22%
MacroGenics	-44.79%	-147.80%	-28.40%

Hyperliquid Strategies has a beta of 1.64, indicating that its stock price is 64% more volatile than the broader market. Comparatively, MacroGenics has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market.

9.5% of Hyperliquid Strategies shares are held by institutional investors. Comparatively, 96.9% of MacroGenics shares are held by institutional investors. 8.5% of Hyperliquid Strategies shares are held by company insiders. Comparatively, 13.6% of MacroGenics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Hyperliquid Strategies beats MacroGenics on 8 of the 14 factors compared between the two stocks.

How does MacroGenics compare to WAVE Life Sciences?

WAVE Life Sciences (NASDAQ:WVE) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends and media sentiment.

In the previous week, WAVE Life Sciences and WAVE Life Sciences both had 2 articles in the media. WAVE Life Sciences' average media sentiment score of 0.50 beat MacroGenics' score of 0.00 indicating that WAVE Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
WAVE Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MacroGenics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

89.7% of WAVE Life Sciences shares are owned by institutional investors. Comparatively, 96.9% of MacroGenics shares are owned by institutional investors. 24.3% of WAVE Life Sciences shares are owned by company insiders. Comparatively, 13.6% of MacroGenics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

MacroGenics has a net margin of -44.79% compared to WAVE Life Sciences' net margin of -255.70%. WAVE Life Sciences' return on equity of -56.76% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
WAVE Life Sciences	-255.70%	-56.76%	-42.80%
MacroGenics	-44.79%	-147.80%	-28.40%

WAVE Life Sciences has a beta of -1.33, indicating that its share price is 233% less volatile than the broader market. Comparatively, MacroGenics has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market.

MacroGenics has higher revenue and earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WAVE Life Sciences	$42.73M	26.79	-$204.38M	-$1.06	N/A
MacroGenics	$149.50M	2.03	-$74.62M	-$1.10	N/A

WAVE Life Sciences currently has a consensus price target of $26.41, indicating a potential upside of 343.90%. MacroGenics has a consensus price target of $5.50, indicating a potential upside of 15.06%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe WAVE Life Sciences is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Summary

WAVE Life Sciences beats MacroGenics on 8 of the 14 factors compared between the two stocks.

How does MacroGenics compare to Collegium Pharmaceutical?

Collegium Pharmaceutical (NASDAQ:COLL) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

Collegium Pharmaceutical has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, MacroGenics has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market.

Collegium Pharmaceutical presently has a consensus target price of $57.50, indicating a potential upside of 61.61%. MacroGenics has a consensus target price of $5.50, indicating a potential upside of 15.06%. Given Collegium Pharmaceutical's stronger consensus rating and higher possible upside, equities research analysts clearly believe Collegium Pharmaceutical is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.83
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

96.9% of MacroGenics shares are held by institutional investors. 1.9% of Collegium Pharmaceutical shares are held by company insiders. Comparatively, 13.6% of MacroGenics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, MacroGenics had 2 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 2 mentions for MacroGenics and 0 mentions for Collegium Pharmaceutical. Collegium Pharmaceutical's average media sentiment score of 1.50 beat MacroGenics' score of 0.00 indicating that Collegium Pharmaceutical is being referred to more favorably in the media.

Company	Overall Sentiment
Collegium Pharmaceutical	Very Positive
MacroGenics	Neutral

Collegium Pharmaceutical has higher revenue and earnings than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$780.57M	1.48	$62.87M	$2.04	17.44
MacroGenics	$149.50M	2.03	-$74.62M	-$1.10	N/A

Collegium Pharmaceutical has a net margin of 9.41% compared to MacroGenics' net margin of -44.79%. Collegium Pharmaceutical's return on equity of 95.18% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	9.41%	95.18%	16.39%
MacroGenics	-44.79%	-147.80%	-28.40%

Summary

Collegium Pharmaceutical beats MacroGenics on 11 of the 16 factors compared between the two stocks.

Get MacroGenics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MGNX vs. The Competition

Export

Metric	MacroGenics	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$298.11M	$8.18B	$6.56B	$12.24B
Dividend Yield	N/A	2.59%	2.69%	5.82%
P/E Ratio	-4.35	15.21	25.17	23.98
Price / Sales	2.03	5.89	553.76	120.62
Price / Cash	N/A	16.83	44.82	54.51
Price / Book	5.43	3.29	10.76	6.41
Net Income	-$74.62M	$226.25M	$3.56B	$337.14M
7 Day Performance	20.71%	-0.96%	1.37%	-0.48%
1 Month Performance	5.52%	-2.77%	0.81%	0.49%
1 Year Performance	256.72%	0.16%	30.53%	28.16%

MacroGenics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MGNX MacroGenics	1.4127 of 5 stars	$4.78 +1.9%	$5.50 +15.1%	+255.3%	$298.11M	$149.50M	N/A	430	High Trading Volume
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180
SVRA Savara	1.6943 of 5 stars	$5.78 +1.6%	$10.14 +75.5%	+167.6%	$1.18B	N/A	N/A	20
PURR Hyperliquid Strategies	2.8076 of 5 stars	$8.14 -11.5%	$9.25 +13.6%	N/A	$1.18B	$1M	N/A	N/A	Options Volume Gap Up
WVE WAVE Life Sciences	2.728 of 5 stars	$6.04 -2.1%	$26.41 +337.3%	-13.2%	$1.16B	$71.80M	N/A	240

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MGNX) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MacroGenics (MGNX) Competitors

MGNX vs. CALT, SVRA, PURR, WVE, and COLL

How does MacroGenics compare to Calliditas Therapeutics AB (publ)?

Summary

How does MacroGenics compare to Savara?

Summary

How does MacroGenics compare to Hyperliquid Strategies?

Summary

How does MacroGenics compare to WAVE Life Sciences?

Summary

How does MacroGenics compare to Collegium Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGNX vs. The Competition

MacroGenics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MacroGenics (MGNX) Competitors

MGNX vs. CALT, SVRA, PURR, WVE, and COLL

How does MacroGenics compare to Calliditas Therapeutics AB (publ)?

Do analysts recommend MGNX or CALT?

Which has more volatility and risk, MGNX or CALT?

Does the media favor MGNX or CALT?

Is MGNX or CALT more profitable?

Which has preferable valuation and earnings, MGNX or CALT?

Do insiders & institutionals believe in MGNX or CALT?

Summary

How does MacroGenics compare to Savara?

Do institutionals & insiders believe in SVRA or MGNX?

Which has better valuation & earnings, SVRA or MGNX?

Does the media favor SVRA or MGNX?

Which has more risk and volatility, SVRA or MGNX?

Is SVRA or MGNX more profitable?

Do analysts recommend SVRA or MGNX?

Summary

How does MacroGenics compare to Hyperliquid Strategies?

Which has better earnings & valuation, PURR or MGNX?

Does the media favor PURR or MGNX?

Do analysts prefer PURR or MGNX?

Is PURR or MGNX more profitable?

Which has more risk & volatility, PURR or MGNX?

Do insiders and institutionals have more ownership in PURR or MGNX?

Summary

How does MacroGenics compare to WAVE Life Sciences?

Does the media favor WVE or MGNX?

Do institutionals and insiders believe in WVE or MGNX?

Is WVE or MGNX more profitable?

Which has more risk and volatility, WVE or MGNX?

Which has higher valuation and earnings, WVE or MGNX?

Do analysts prefer WVE or MGNX?

Summary

How does MacroGenics compare to Collegium Pharmaceutical?

Which has more risk and volatility, COLL or MGNX?

Do analysts recommend COLL or MGNX?

Do institutionals & insiders believe in COLL or MGNX?

Does the media favor COLL or MGNX?

Which has preferable earnings and valuation, COLL or MGNX?

Is COLL or MGNX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGNX vs. The Competition

MacroGenics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools